skip to Main Content

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry


Brief Summary:

The purpose of this registry is to compile characteristics of world-wide outcomes for the use
of Boston Scientific’s commercially available Vercise DBS system in the treatment of
Parkinson’s disease.

Additionally, the utilization of Guide XT (GXT) System when used as a planning tool for the
programming of patients with the Boston Scientific’s Vercise DBS Systems is also evaluated.


Key Inclusion Criteria:

– Meets criteria established in locally applicable Vercise System Direction for Use

– At least 18 years old

Key Exclusion Criteria:

– Meets any contraindication in the Vercise System locally applicable Directions for Use

Subjects with significant cognitive or psychiatric impairment may be excluded in the
evaluation of GXT.


  • Boston Scientific Clinical Research Toll-Free Number, Valencia, California, United States, 91355
Back To Top